A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02222493

Enrollment

650

Registered

2014-08-21

Start date

2014-08-26

Completion date

2017-06-01

Last updated

2018-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Phase 3, infliximab, rheumatoid arthritis

Brief summary

The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.

Interventions

BIOLOGICALPF-06438179

PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

BIOLOGICALInfliximab

Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months. At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline. HS-CRP equal or greater than 10 mg/L. Must have received methotrexate for at least 12 weeks and be on a stable dose for at least 4 weeks.

Exclusion criteria

Evidence of untreated or inadequately treated latent or active TB. Evidence or history of moderate or severe heart failure (NYHA Class III/IV) Infection requiring hospitalization or parenteral antimicrobial therapy judged clinically significant by the investigator within 6 months prior to first dose of study drug.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1	Week 14	ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index \[HAQ-DI\]); and C-Reactive Protein (CRP).

Secondary

Measure	Time frame	Description
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 38, 46 and 54 (pre-dose)	ACR20 response: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 62, 70 and 78	ACR20 response: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	Week 2, 4, 6, 12, 14, 22 and 30 (pre-dose)	ACR50 response: \>=50% improvement in tender joint count, \>=50% improvement in swollen joint count improvement and \>=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: \>=70% improvement in tender joint count, \>=70% improvement in swollen joint count improvement and \>=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 38, 46 and 54 (pre-dose)	ACR50 response: \>=50% improvement in tender joint count, \>=50% improvement in swollen joint count improvement and \>=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: \>=70% improvement in tender joint count, \>=70% improvement in swollen joint count improvement and \>=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	Week 62, 70 and 78	ACR50 response: \>=50% improvement in tender joint count, \>=50% improvement in swollen joint count improvement and \>=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: \>=70% improvement in tender joint count, \>=70% improvement in swollen joint count improvement and \>=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.
Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30	DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale \[VAS\] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (\<)2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and greater than (\>) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	Baseline (Week 30 pre-dose), Week 38, 46 and 54	DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter \[mm\]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	Baseline (Week 54 pre-dose), Week 62, 70 and 78	DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)	ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=\<) 1 or the score on the simplified disease activity index (SDAI) was =\<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 \<3.2: low disease activity, DAS28 \<2.6: remission.
Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	Week 38, 46 and 54 (pre-dose)	ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =\<1 or the score on the SDAI was =\<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 \<3.2: low disease activity, DAS28 \<2.6: remission.
Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	Week 62, 70 and 78	ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =\<1 or the score on the SDAI was =\<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 \<3.2: low disease activity, DAS28 \<2.6: remission.
Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)	EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of \>1.2 with DAS28 =\<3.2; moderate response = DAS28 change of \>0.6 to =\<1.2 with DAS28 \>3.2-5.1 and no-response = DAS28 change of =\<0.6 with DAS28 \>5.1.
Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38, 46 and Week 54 (pre-dose)	EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of \>1.2 with DAS28 =\<3.2; moderate response = DAS28 change of \>0.6 to =\<1.2 with DAS28 \>3.2-5.1 and no-response = DAS28 change of =\<0.6 with DAS28 \>5.1.
Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62, 70 and Week 78	EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of \>1.2 with DAS28 =\<3.2; moderate response = DAS28 change of \>0.6 to =\<1.2 with DAS28 \>3.2-5.1 and no-response = DAS28 change of =\<0.6 with DAS28 \>5.1.
Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and Week 30	Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1	Baseline (Day 1) up to Week 30	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 30 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2	Baseline (Week 30 pre-dose) up to Week 54	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 54 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3	Baseline (Week 54 pre-dose) up to Week 78	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Week 78 that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious adverse events.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 1	Baseline (Day 1) up to Week 30	AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 2, 4, 6, 12, 22 and 30 (pre-dose)	ACR20 response: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 3	Baseline (Week 54 pre-dose) up to Week 78	AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.
Number of Participants With Laboratory Abnormalities: Period 1	Baseline (Day 1) up to Week 30	Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: \<0.8\lower limit of normal (LLN); platelets: \>1.75\upper limit of normal (ULN); white blood cell count: \<0.6\LLN; basophils, eosinophils, monocytes: \>1.2\ULN. liver function: bilirubin: \>1.5\ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\ULN; protein, albumin: \<0.8\LLN\>\</0\>1.2\ULN; renal function:blood urea nitrogen,creatinine: \>1.3\ULN; uric acid: \>1.2\ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\LLN,\>1.1\ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\LLN,\>1.5\ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.
Number of Participants With Laboratory Abnormalities: Period 2	Baseline (Week 30 pre-dose) up to Week 54	Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: \<0.8\lower limit of normal (LLN); platelets: \>1.75\upper limit of normal (ULN); white blood cell count: \<0.6\LLN; basophils, eosinophils, monocytes: \>1.2\ULN. liver function: bilirubin: \>1.5\ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\ULN; protein, albumin: \<0.8\LLN\>\</0\>1.2\ULN; renal function:blood urea nitrogen,creatinine: \>1.3\ULN; uric acid: \>1.2\ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\LLN,\>1.1\ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\LLN,\>1.5\ULN). Participants with any laboratory abnormality in Period 2 were reported in this outcome measure.
Number of Participants With Laboratory Abnormalities: Period 3	Baseline (Week 54 pre-dose) up to Week 78	Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: \<0.8\lower limit of normal (LLN); platelets: \>1.75\upper limit of normal (ULN); white blood cell count: \<0.6\LLN; basophils, eosinophils, monocytes: \>1.2\ULN. liver function: bilirubin: \>1.5\ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\ULN; protein, albumin: \<0.8\LLN\>\</0\>1.2\ULN; renal function:blood urea nitrogen,creatinine: \>1.3\ULN; uric acid: \>1.2\ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\LLN,\>1.1\ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\LLN,\>1.5\ULN). Participants with any laboratory abnormality in Period 3 were reported in this outcome measure.
Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Baseline (Week 30 pre-dose), Week 38, 46 and Week 54	Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Baseline (Week 54 pre-dose), Week 62, 70 and 78	Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30	PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, Considering all the ways your arthritis affects you, how are you feeling today? and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	Baseline (Week 30 pre-dose), Week 38, 46 and 54	PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, Considering all the ways your arthritis affects you, how are you feeling today? and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	Baseline (Week 54 pre-dose), Week 62, 70 and 78	PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, Considering all the ways your arthritis affects you, how are you feeling today? and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30	—
Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Baseline (Week 30 pre-dose), Week 38, 46 and 54	—
Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Baseline (Week 54 pre-dose), Week 62, 70 and 78	—
Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1	Baseline (Day 1) up to Week 30	ADA positive results was defined as ADA titer level \>=1.30 and NAb positive was defined as NAb titer level \>=0.70.
Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 2	Baseline (Week 30 pre-dose) up to Week 54	ADA positive results was defined as ADA titer level \>=1.30 and NAb positive was defined as NAb titer level \>=0.70.
Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 3	Baseline (Week 54 pre-dose) up to Week 78	ADA positive results was defined as ADA titer level \>=1.30 and NAb positive was defined as NAb titer level \>=0.70.
Serum Concentration Versus Time Summary: Period 1	Pre dose on Day 1, 15, 43, 99, 155 and 211; 2 hours post dose on Day 1 and 99; and 336 hours post dose on Day 29	—
Serum Concentration Versus Time Summary: Period 2	Pre dose on Day 211, 267, 379 and 547	—
Serum Concentration Versus Time Summary: Period 3	Pre dose on Day 379, 435 and 547	—
Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Grade 3 or Higher Severity: Period 2	Baseline (Week 30 pre-dose) up to Week 54	AEs were graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) Version 4.03 as Grades 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life threatening AEs and Grade 5= death related to AE. AEs of Grade 3 and higher severity are reported in this outcome measure.

Countries

Australia, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Czechia, Georgia, Germany, Guatemala, Hungary, Israel, Japan, Jordan, Lithuania, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russia, Serbia, South Africa, South Korea, Tunisia, Ukraine, United Kingdom, United States

Participant flow

Pre-assignment details

A total of 1603 participants were screened after signing an informed consent form, of whom 650 participants were randomized to receive study treatment. One (1) participant in the PF-06438179 arm was screened and randomized by 2 different study site personnel, and no data were collected for the participant's second randomization.

Participants by arm

Arm	Count
PF-06438179 Participants received intravenous infusions of PF-06438179 at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2, when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.	324
Infliximab-EU Remicade (INX) Participants received intravenous infusions of INX at 3 mg/kg on Weeks 0, 2, 6 followed by a maintenance dose every 8 weeks at Weeks 14 and 22 in Period 1 which ended with the completion of the Week 30 pre-dose assessments. For participants who failed to achieve a minimum clinical response or lost clinical response (after Week 14 assessments), dose was increased to 5 mg/kg per infusion every 8 weeks. Participants initially randomized to PF-06438179 continued to blindly receive PF-06438179 in Period 2. A second randomization was blindly performed prior to dosing at Week 30 (at the beginning of Period 2), when participants initially randomized to INX were re-randomized in a 1:1 ratio, with 50% of the participants switching to PF-06438179 and the other 50% of participants remaining on the INX arm. Period 3 started with dosing at Week 54 where all participants began open label treatment with PF-06438179.	326
Total	650

Withdrawals & dropouts

Period	Reason	FG000	FG001
Period 1: First Dose-Week 30 (Pre-dose)	Adverse Event	18	20
Period 1: First Dose-Week 30 (Pre-dose)	Death	2	2
Period 1: First Dose-Week 30 (Pre-dose)	Insufficient clinical response	0	7
Period 1: First Dose-Week 30 (Pre-dose)	Lost to Follow-up	0	1
Period 1: First Dose-Week 30 (Pre-dose)	Non-compliance with study treatment	1	0
Period 1: First Dose-Week 30 (Pre-dose)	Other	4	0
Period 1: First Dose-Week 30 (Pre-dose)	Pregnancy	2	0
Period 1: First Dose-Week 30 (Pre-dose)	Protocol Violation	5	1
Period 1: First Dose-Week 30 (Pre-dose)	Randomized but not treated	1	0
Period 1: First Dose-Week 30 (Pre-dose)	Withdrawal by Subject	11	9
Period 2: Week30 Dosing-Week54(Pre-dose)	Adverse Event	22	9
Period 2: Week30 Dosing-Week54(Pre-dose)	Death	1	0
Period 2: Week30 Dosing-Week54(Pre-dose)	Insufficient clinical response	9	3
Period 2: Week30 Dosing-Week54(Pre-dose)	Lost to Follow-up	1	1
Period 2: Week30 Dosing-Week54(Pre-dose)	Non-compliance with study treatment	1	0
Period 2: Week30 Dosing-Week54(Pre-dose)	Other	3	0
Period 2: Week30 Dosing-Week54(Pre-dose)	Withdrawal by Subject	6	4
Period 3: Week 54 Dosing-Week 78 Visit	Adverse Event	14	0
Period 3: Week 54 Dosing-Week 78 Visit	Insufficient clinical response	3	0
Period 3: Week 54 Dosing-Week 78 Visit	Non-compliance with study treatment	1	0
Period 3: Week 54 Dosing-Week 78 Visit	Other	4	0
Period 3: Week 54 Dosing-Week 78 Visit	Withdrawal by Subject	9	0

Baseline characteristics

Characteristic	PF-06438179	Infliximab-EU Remicade (INX)	Total
Age, Continuous	52.8 years STANDARD_DEVIATION 13.3	52.8 years STANDARD_DEVIATION 12.9	52.8 years STANDARD_DEVIATION 13.1
Sex: Female, Male Female	258 Participants	264 Participants	522 Participants
Sex: Female, Male Male	66 Participants	62 Participants	128 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	38 / 323	35 / 326	8 / 280	11 / 143	6 / 143	0 / 253	0 / 126	0 / 126
serious Total, serious adverse events	16 / 323	20 / 326	13 / 280	11 / 143	4 / 143	3 / 253	3 / 126	6 / 126

Outcome results

Primary

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1

ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity (PGA); physician global assessment of disease activity; self-assessed disability (health assessment questionnaire-disability index \[HAQ-DI\]); and C-Reactive Protein (CRP).

Time frame: Week 14

Population: The ITT Population was defined as all participants who were randomized to study treatment. The primary analyses for ACR20 at Week 14 were performed with the missing data imputed using a non-responder imputation method.

Arm	Measure	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1	198 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1	207 participants

Comparison: Score statistic method95% CI: [-9.92, 5.11]

Comparison: Score statistic method90% CI: [-8.75, 4.02]

Secondary

Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1

DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on visual analogue scale \[VAS\] from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) less than (\<)2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and greater than (\>) 5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.

Time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Baseline)	5.950 units on a scale	Standard Deviation 0.9577
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 2)	-1.213 units on a scale	Standard Deviation 0.928
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 4)	-1.596 units on a scale	Standard Deviation 1.1259
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 6)	-1.710 units on a scale	Standard Deviation 1.1959
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 12)	-1.898 units on a scale	Standard Deviation 1.3516
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 14)	-1.901 units on a scale	Standard Deviation 1.4125
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 22)	-2.005 units on a scale	Standard Deviation 1.4236
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 30)	-2.140 units on a scale	Standard Deviation 1.4197
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Baseline)	1.623 units on a scale	Standard Deviation 0.6485
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 2)	-0.317 units on a scale	Standard Deviation 0.41
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 4)	-0.472 units on a scale	Standard Deviation 0.4728
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 6)	-0.496 units on a scale	Standard Deviation 0.5505
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 12)	-0.535 units on a scale	Standard Deviation 0.5795
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 14)	-0.572 units on a scale	Standard Deviation 0.591
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 22)	-0.588 units on a scale	Standard Deviation 0.6061
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 30)	-0.621 units on a scale	Standard Deviation 0.6484
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 30)	-0.612 units on a scale	Standard Deviation 0.6546
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Baseline)	5.983 units on a scale	Standard Deviation 0.921
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Baseline)	1.586 units on a scale	Standard Deviation 0.649
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 2)	-1.241 units on a scale	Standard Deviation 0.8879
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 12)	-0.524 units on a scale	Standard Deviation 0.5857
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 4)	-1.605 units on a scale	Standard Deviation 1.0881
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 2)	-0.328 units on a scale	Standard Deviation 0.437
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 6)	-1.750 units on a scale	Standard Deviation 1.0885
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 22)	-0.569 units on a scale	Standard Deviation 0.5958
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 12)	-1.885 units on a scale	Standard Deviation 1.2142
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 4)	-0.477 units on a scale	Standard Deviation 0.4861
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 14)	-1.827 units on a scale	Standard Deviation 1.3019
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 14)	-0.531 units on a scale	Standard Deviation 0.5876
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 22)	-2.002 units on a scale	Standard Deviation 1.2972
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	HAQ-DI (Change at Week 6)	-0.520 units on a scale	Standard Deviation 0.5022
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	DAS28-CRP (Change at Week 30)	-2.117 units on a scale	Standard Deviation 1.2738

Secondary

Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2

DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 millimeter \[mm\]; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.

Time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54

Population: The ITT Population was defined as all participants who were randomized to study treatment. Here, Number of Participants Analyzed signifies participants who were evaluable for this outcome measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Baseline)	3.765 units on a scale	Standard Deviation 1.4629
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 38)	-0.181 units on a scale	Standard Deviation 0.9574
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 46)	-0.228 units on a scale	Standard Deviation 1.0453
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 54)	-0.275 units on a scale	Standard Deviation 1.1338
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Baseline)	0.978 units on a scale	Standard Deviation 0.7042
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 38)	-0.019 units on a scale	Standard Deviation 0.3328
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 46)	-0.043 units on a scale	Standard Deviation 0.3774
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 54)	-0.026 units on a scale	Standard Deviation 0.4407
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 46)	0.048 units on a scale	Standard Deviation 1.2584
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 46)	0.014 units on a scale	Standard Deviation 0.3823
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 54)	-0.109 units on a scale	Standard Deviation 1.1801
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Baseline)	0.913 units on a scale	Standard Deviation 0.6634
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 38)	0.019 units on a scale	Standard Deviation 0.2889
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Baseline)	3.819 units on a scale	Standard Deviation 1.3624
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 38)	0.036 units on a scale	Standard Deviation 0.8686
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 54)	0.017 units on a scale	Standard Deviation 0.4399
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 46)	-0.017 units on a scale	Standard Deviation 1.0692
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 38)	-0.059 units on a scale	Standard Deviation 0.8756
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Baseline)	3.781 units on a scale	Standard Deviation 1.2547
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	DAS28-CRP (Change at Week 54)	-0.057 units on a scale	Standard Deviation 1.2339
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 46)	0.035 units on a scale	Standard Deviation 0.4325
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 38)	0.007 units on a scale	Standard Deviation 0.3688
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Baseline)	0.951 units on a scale	Standard Deviation 0.6481
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 38, 46 and 54: Period 2	HAQ-DI (Change at Week 54)	-0.044 units on a scale	Standard Deviation 0.3881

Secondary

Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3

DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity. HAQ-DI assess degree of difficulty a participant experienced (past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.

Time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78

Population: The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3. Here, Number of Participants Analyzed signifies participants who were evaluable for this outcome measure.

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Baseline)	3.386 units on a scale	Standard Deviation 1.3229
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 62)	-0.072 units on a scale	Standard Deviation 0.915
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 70)	-0.157 units on a scale	Standard Deviation 0.9502
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 78)	-0.236 units on a scale	Standard Deviation 1.0361
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Baseline)	0.905 units on a scale	Standard Deviation 0.705
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 62)	-0.024 units on a scale	Standard Deviation 0.3126
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 70)	-0.046 units on a scale	Standard Deviation 0.3502
Period 1: PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 78)	-0.079 units on a scale	Standard Deviation 0.3869
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 70)	-0.168 units on a scale	Standard Deviation 0.8421
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 70)	-0.027 units on a scale	Standard Deviation 0.2758
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 78)	-0.269 units on a scale	Standard Deviation 0.9759
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Baseline)	0.893 units on a scale	Standard Deviation 0.6691
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 62)	0.021 units on a scale	Standard Deviation 0.2989
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Baseline)	3.561 units on a scale	Standard Deviation 1.3123
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 62)	-0.004 units on a scale	Standard Deviation 0.819
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 78)	-0.022 units on a scale	Standard Deviation 0.3521
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 70)	-0.162 units on a scale	Standard Deviation 0.797
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 62)	-0.154 units on a scale	Standard Deviation 0.684
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Baseline)	3.594 units on a scale	Standard Deviation 1.2572
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	DAS28-CRP (Change at Week 78)	-0.215 units on a scale	Standard Deviation 1.0584
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 70)	0.030 units on a scale	Standard Deviation 0.295
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 62)	0.008 units on a scale	Standard Deviation 0.2942
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Baseline)	0.883 units on a scale	Standard Deviation 0.6109
Period 2: INX/PF-06438179	Change From Baseline in Disease Activity Score-CRP (4 Variables) (DAS28-4 [CRP]) and HAQ-DI at Week 62, 70 and 78: Period 3	HAQ-DI (Change at Week 78)	0.001 units on a scale	Standard Deviation 0.38

Secondary

Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1

Time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Baseline	25.916 milligram/litres	Standard Deviation 24.3118
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 2	-17.183 milligram/litres	Standard Deviation 20.8107
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 4	-15.555 milligram/litres	Standard Deviation 19.5227
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 6	-14.078 milligram/litres	Standard Deviation 20.4984
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 12	-12.502 milligram/litres	Standard Deviation 23.9435
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 14	-12.613 milligram/litres	Standard Deviation 23.2548
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 22	-11.195 milligram/litres	Standard Deviation 24.5225
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 30	-12.165 milligram/litres	Standard Deviation 25.6612
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 30	-12.390 milligram/litres	Standard Deviation 30.0352
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Baseline	25.366 milligram/litres	Standard Deviation 28.4866
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 12	-12.525 milligram/litres	Standard Deviation 27.8736
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 2	-16.140 milligram/litres	Standard Deviation 24.2442
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 22	-11.422 milligram/litres	Standard Deviation 31.061
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 4	-13.407 milligram/litres	Standard Deviation 33.9136
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 14	-12.392 milligram/litres	Standard Deviation 29.3267
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Change at Week 6	-13.247 milligram/litres	Standard Deviation 27.7801

Secondary

Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2

Time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Baseline	12.970 milligrams/litres	Standard Deviation 19.1927
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 38	0.496 milligrams/litres	Standard Deviation 18.7859
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 46	1.210 milligrams/litres	Standard Deviation 16.1727
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 54	0.639 milligrams/litres	Standard Deviation 21.1226
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 54	2.988 milligrams/litres	Standard Deviation 24.5492
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Baseline	14.427 milligrams/litres	Standard Deviation 21.1595
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 46	3.996 milligrams/litres	Standard Deviation 24.4986
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 38	1.805 milligrams/litres	Standard Deviation 19.5138
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 54	1.264 milligrams/litres	Standard Deviation 13.6788
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 38	0.093 milligrams/litres	Standard Deviation 14.8441
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Change at Week 46	0.798 milligrams/litres	Standard Deviation 15.7687
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 38, 46 and 54: Period 2	Baseline	10.847 milligrams/litres	Standard Deviation 14.8018

Secondary

Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3

Time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Baseline	13.112 milligrams/litres	Standard Deviation 21.3781
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 62	-0.635 milligrams/litres	Standard Deviation 19.966
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 70	-0.320 milligrams/litres	Standard Deviation 23.1234
Period 1: PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 78	-1.660 milligrams/litres	Standard Deviation 19.634
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 78	-3.565 milligrams/litres	Standard Deviation 23.98
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Baseline	16.096 milligrams/litres	Standard Deviation 24.1595
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 70	-4.199 milligrams/litres	Standard Deviation 22.3368
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 62	-3.648 milligrams/litres	Standard Deviation 21.6177
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 78	0.811 milligrams/litres	Standard Deviation 14.7061
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 62	-0.541 milligrams/litres	Standard Deviation 9.3198
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Change at Week 70	-0.339 milligrams/litres	Standard Deviation 11.7095
Period 2: INX/PF-06438179	Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Concentration at Week 62, 70 and 78: Period 3	Baseline	11.985 milligrams/litres	Standard Deviation 13.8159

Secondary

Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1

PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, Considering all the ways your arthritis affects you, how are you feeling today? and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.

Time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and 30

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at week 22)	-27.844 units on a scale	Standard Deviation 27.0039
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 2)	-15.724 units on a scale	Standard Deviation 21.9589
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 4)	-21.609 units on a scale	Standard Deviation 22.3825
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 6)	-23.917 units on a scale	Standard Deviation 25.0213
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 12)	-25.364 units on a scale	Standard Deviation 25.6602
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 14)	-26.131 units on a scale	Standard Deviation 26.8712
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Baseline)	63.514 units on a scale	Standard Deviation 20.5903
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 30)	-29.150 units on a scale	Standard Deviation 27.9802
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Baseline)	65.340 units on a scale	Standard Deviation 20.7209
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 2)	-17.262 units on a scale	Standard Deviation 22.8767
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 4)	-23.393 units on a scale	Standard Deviation 23.3769
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 6)	-25.536 units on a scale	Standard Deviation 24.8041
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 12)	-26.882 units on a scale	Standard Deviation 25.327
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 14)	-27.583 units on a scale	Standard Deviation 26.7955
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 22)	-28.558 units on a scale	Standard Deviation 27.5077
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 30)	-29.186 units on a scale	Standard Deviation 28.6488
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Baseline)	65.362 units on a scale	Standard Deviation 16.252
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 2)	-21.913 units on a scale	Standard Deviation 18.5574
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 4)	-29.724 units on a scale	Standard Deviation 19.2226
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 6)	-33.319 units on a scale	Standard Deviation 20.1143
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 12)	-34.827 units on a scale	Standard Deviation 19.8162
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 14)	-35.870 units on a scale	Standard Deviation 21.4707
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 22)	-37.542 units on a scale	Standard Deviation 20.8619
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 30)	-39.842 units on a scale	Standard Deviation 22.0276
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 22)	-36.118 units on a scale	Standard Deviation 20.6564
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Baseline)	63.098 units on a scale	Standard Deviation 21.5442
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 12)	-26.535 units on a scale	Standard Deviation 26.3998
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 2)	-15.360 units on a scale	Standard Deviation 19.4328
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 4)	-27.905 units on a scale	Standard Deviation 17.9803
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 4)	-20.552 units on a scale	Standard Deviation 21.267
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 14)	-25.323 units on a scale	Standard Deviation 26.8562
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 6)	-22.797 units on a scale	Standard Deviation 22.9133
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 14)	-34.175 units on a scale	Standard Deviation 20.6526
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 12)	-25.829 units on a scale	Standard Deviation 24.8304
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 22)	-26.486 units on a scale	Standard Deviation 26.7141
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 14)	-25.077 units on a scale	Standard Deviation 25.0536
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 6)	-30.958 units on a scale	Standard Deviation 18.9303
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at week 22)	-25.788 units on a scale	Standard Deviation 25.3225
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 30)	-28.814 units on a scale	Standard Deviation 28.5929
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PAAP (Change at Week 30)	-28.853 units on a scale	Standard Deviation 26.7252
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 30)	-36.666 units on a scale	Standard Deviation 22.1598
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Baseline)	63.752 units on a scale	Standard Deviation 22.9105
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Baseline)	64.126 units on a scale	Standard Deviation 16.722
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 2)	-16.504 units on a scale	Standard Deviation 20.3188
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 12)	-33.919 units on a scale	Standard Deviation 19.702
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 4)	-21.355 units on a scale	Standard Deviation 23.6005
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGAA (Change at Week 2)	-20.143 units on a scale	Standard Deviation 17.1407
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 2, 4, 6, 12, 14, 22, 30: Period 1	PGA (Change at Week 6)	-23.314 units on a scale	Standard Deviation 24.2005

Secondary

Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2

Time frame: Baseline (Week 30 pre-dose), Week 38, 46 and 54

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Baseline)	33.137 units on a scale	Standard Deviation 24.2922
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 38)	-0.014 units on a scale	Standard Deviation 18.7502
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 46)	-2.230 units on a scale	Standard Deviation 20.0201
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 54)	-1.416 units on a scale	Standard Deviation 20.7823
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Baseline)	35.104 units on a scale	Standard Deviation 24.8444
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 38)	-1.628 units on a scale	Standard Deviation 19.1471
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 46)	-3.171 units on a scale	Standard Deviation 20.305
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 54)	-2.929 units on a scale	Standard Deviation 20.9396
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Baseline)	25.124 units on a scale	Standard Deviation 19.0943
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 38)	-1.254 units on a scale	Standard Deviation 12.4789
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 46)	-2.470 units on a scale	Standard Deviation 13.9135
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 54)	-2.252 units on a scale	Standard Deviation 17.0422
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 54)	-3.398 units on a scale	Standard Deviation 20.0381
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Baseline)	33.331 units on a scale	Standard Deviation 22.2738
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 46)	0.558 units on a scale	Standard Deviation 20.661
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Baseline)	27.294 units on a scale	Standard Deviation 18.8148
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 38)	1.440 units on a scale	Standard Deviation 14.9902
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 38)	1.582 units on a scale	Standard Deviation 16.0776
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 46)	0.625 units on a scale	Standard Deviation 20.0163
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 46)	1.087 units on a scale	Standard Deviation 21.5811
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 54)	-0.538 units on a scale	Standard Deviation 21.1331
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Baseline)	33.268 units on a scale	Standard Deviation 22.2621
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 54)	-0.492 units on a scale	Standard Deviation 20.8
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 38)	0.588 units on a scale	Standard Deviation 16.5232
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 54)	1.365 units on a scale	Standard Deviation 24.8362
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Baseline)	34.029 units on a scale	Standard Deviation 22.7172
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 38)	-1.852 units on a scale	Standard Deviation 15.4699
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 38)	-1.086 units on a scale	Standard Deviation 17.5787
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 46)	0.535 units on a scale	Standard Deviation 21.3947
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGA (Change at Week 54)	0.776 units on a scale	Standard Deviation 23.8743
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 46)	-0.700 units on a scale	Standard Deviation 18.8038
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Baseline)	32.559 units on a scale	Standard Deviation 22.2702
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 38)	-0.705 units on a scale	Standard Deviation 18.9147
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Baseline)	26.091 units on a scale	Standard Deviation 17.9503
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PAAP (Change at Week 46)	2.188 units on a scale	Standard Deviation 20.7319
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 38, 46 and 54: Period 2	PGAA (Change at Week 54)	-2.969 units on a scale	Standard Deviation 20.1498

Secondary

Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3

Time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 70)	-1.764 units on a scale	Standard Deviation 18.7038
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 62)	-0.025 units on a scale	Standard Deviation 15.8259
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Baseline)	30.395 units on a scale	Standard Deviation 23.7412
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 78)	-2.217 units on a scale	Standard Deviation 15.3894
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 70)	-2.948 units on a scale	Standard Deviation 18.1105
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 62)	0.240 units on a scale	Standard Deviation 16.2724
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 70)	-3.217 units on a scale	Standard Deviation 14.1581
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 78)	-3.552 units on a scale	Standard Deviation 18.876
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Baseline)	21.305 units on a scale	Standard Deviation 17.6278
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 78)	-2.880 units on a scale	Standard Deviation 19.6643
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Baseline)	30.841 units on a scale	Standard Deviation 23.7807
Period 1: PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 62)	-0.381 units on a scale	Standard Deviation 13.681
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Baseline)	31.130 units on a scale	Standard Deviation 23.3603
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 62)	2.659 units on a scale	Standard Deviation 14.6314
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 70)	-1.160 units on a scale	Standard Deviation 12.7665
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 78)	0.681 units on a scale	Standard Deviation 15.0989
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Baseline)	31.659 units on a scale	Standard Deviation 23.29
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Baseline)	21.780 units on a scale	Standard Deviation 17.3354
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 62)	0.276 units on a scale	Standard Deviation 12.2744
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 70)	0.101 units on a scale	Standard Deviation 14.426
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 70)	-0.297 units on a scale	Standard Deviation 15.4108
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 62)	1.463 units on a scale	Standard Deviation 13.6899
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 78)	-2.900 units on a scale	Standard Deviation 18.0663
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 78)	-2.339 units on a scale	Standard Deviation 17.0453
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 70)	-0.970 units on a scale	Standard Deviation 16.717
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 62)	-2.226 units on a scale	Standard Deviation 15.3415
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 70)	-2.093 units on a scale	Standard Deviation 16.2677
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Change at Week 78)	-3.758 units on a scale	Standard Deviation 19.5447
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Baseline)	31.225 units on a scale	Standard Deviation 22.9366
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 62)	-1.790 units on a scale	Standard Deviation 16.674
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGA (Baseline)	32.710 units on a scale	Standard Deviation 22.6365
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PAAP (Change at Week 78)	-3.918 units on a scale	Standard Deviation 20.9632
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Baseline)	20.705 units on a scale	Standard Deviation 16.9587
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 62)	-0.499 units on a scale	Standard Deviation 12.9483
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 70)	-0.810 units on a scale	Standard Deviation 15.0274
Period 2: INX/PF-06438179	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP), Patient's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 62, 70 and 78: Period 3	PGAA (Change at Week 78)	-0.159 units on a scale	Standard Deviation 17.2024

Secondary

Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1

Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.

Time frame: Baseline (Day 1), Week 2, 4, 6, 12, 14, 22 and Week 30

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Baseline)	24.7 joints	Standard Deviation 13.9
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 2)	-5.9 joints	Standard Deviation 8.78
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 4)	-9.5 joints	Standard Deviation 10.02
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 6)	-10.6 joints	Standard Deviation 11.17
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 12)	-12.1 joints	Standard Deviation 11.84
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 14)	-11.8 joints	Standard Deviation 12.5
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 22)	-13.2 joints	Standard Deviation 12.62
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 30)	-14.4 joints	Standard Deviation 13.19
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Baseline)	16.1 joints	Standard Deviation 9.44
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 2)	-5.5 joints	Standard Deviation 6.89
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 4)	-7.8 joints	Standard Deviation 7.75
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 6)	-8.6 joints	Standard Deviation 7.99
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 12)	-9.6 joints	Standard Deviation 8.61
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 14)	-9.3 joints	Standard Deviation 8.87
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 22)	-10.5 joints	Standard Deviation 8.77
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 30)	-11.0 joints	Standard Deviation 9.33
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 30)	-10.7 joints	Standard Deviation 8.52
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Baseline)	25.8 joints	Standard Deviation 12.89
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Baseline)	16.3 joints	Standard Deviation 8.7
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 2)	-7.5 joints	Standard Deviation 8.39
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 12)	-9.6 joints	Standard Deviation 8.39
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 4)	-10.4 joints	Standard Deviation 9.41
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 2)	-5.7 joints	Standard Deviation 7.27
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 6)	-12.1 joints	Standard Deviation 10.12
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 22)	-10.2 joints	Standard Deviation 7.94
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 12)	-13.2 joints	Standard Deviation 11.51
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 4)	-7.9 joints	Standard Deviation 7.39
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 14)	-13.0 joints	Standard Deviation 12.15
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 14)	-9.6 joints	Standard Deviation 8.44
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 22)	-15.2 joints	Standard Deviation 12.93
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Swollen joint count (Change at Week 6)	-9.0 joints	Standard Deviation 7.92
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 2, 4, 6, 12, 14, 22 and 30: Period 1	Tender joint count (Change at Week 30)	-15.6 joints	Standard Deviation 12.57

Secondary

Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2

Time frame: Baseline (Week 30 pre-dose), Week 38, 46 and Week 54

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Baseline)	10.2 joints	Standard Deviation 11.74
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 38)	-1.3 joints	Standard Deviation 6.74
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 46)	-1.6 joints	Standard Deviation 7.87
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 54)	-1.7 joints	Standard Deviation 7.96
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Baseline)	4.9 joints	Standard Deviation 6.46
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 38)	-0.8 joints	Standard Deviation 4.19
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 46)	-1.2 joints	Standard Deviation 5.2
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 54)	-1.3 joints	Standard Deviation 5.52
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 46)	-1.0 joints	Standard Deviation 9.32
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 46)	0.0 joints	Standard Deviation 5.54
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 54)	-1.7 joints	Standard Deviation 10.23
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Baseline)	5.3 joints	Standard Deviation 6.57
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 38)	-0.1 joints	Standard Deviation 4.9
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Baseline)	10.2 joints	Standard Deviation 11.96
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 38)	-0.5 joints	Standard Deviation 8.86
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 54)	-0.9 joints	Standard Deviation 7.02
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 46)	-0.8 joints	Standard Deviation 7.77
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 38)	-1.0 joints	Standard Deviation 6.03
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Baseline)	9.1 joints	Standard Deviation 8.89
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Tender joint count (Change at Week 54)	-0.5 joints	Standard Deviation 9.03
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 46)	-0.5 joints	Standard Deviation 4.22
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 38)	-0.3 joints	Standard Deviation 3.93
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Baseline)	4.6 joints	Standard Deviation 5.35
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 38, 46 and 54: Period 2	Swollen joint count (Change at Week 54)	-0.7 joints	Standard Deviation 4.1

Secondary

Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3

Time frame: Baseline (Week 54 pre-dose), Week 62, 70 and 78

Arm	Measure	Group	Value (MEAN)	Dispersion
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Baseline)	7.5 joints	Standard Deviation 9.51
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 62)	-0.7 joints	Standard Deviation 5.88
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 70)	-1.4 joints	Standard Deviation 6.32
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 78)	-1.7 joints	Standard Deviation 6.57
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Baseline)	3.4 joints	Standard Deviation 5.72
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 62)	-0.3 joints	Standard Deviation 3.76
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 70)	-0.7 joints	Standard Deviation 4.6
Period 1: PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 78)	-0.9 joints	Standard Deviation 4.63
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 70)	-0.6 joints	Standard Deviation 5.14
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 70)	-0.4 joints	Standard Deviation 4.12
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 78)	-1.0 joints	Standard Deviation 5.82
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Baseline)	4.1 joints	Standard Deviation 5.16
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 62)	0.0 joints	Standard Deviation 4.41
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Baseline)	7.5 joints	Standard Deviation 9.21
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 62)	0.3 joints	Standard Deviation 5.21
Period 1: Infliximab-EU Remicade (INX)	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 78)	-0.5 joints	Standard Deviation 4
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 70)	-1.0 joints	Standard Deviation 5.51
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 62)	-0.8 joints	Standard Deviation 5.18
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Baseline)	7.4 joints	Standard Deviation 7.99
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Tender joint count (Change at Week 78)	-1.4 joints	Standard Deviation 6.63
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 70)	-0.5 joints	Standard Deviation 2.48
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 62)	-0.3 joints	Standard Deviation 2.72
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Baseline)	3.5 joints	Standard Deviation 4.28
Period 2: INX/PF-06438179	Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 62, 70 and 78: Period 3	Swollen joint count (Change at Week 78)	-0.2 joints	Standard Deviation 3.14

Secondary

Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1

ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and patient's global assessment of arthritis (PGA) all were less than or equal to (=\<) 1 or the score on the simplified disease activity index (SDAI) was =\<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 \<3.2: low disease activity, DAS28 \<2.6: remission.

Time frame: Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 2)	2 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 4)	10 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 6)	12 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 12)	28 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 14)	27 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 22)	25 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 30, pre-dose)	30 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 2)	9 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 4)	28 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 6)	40 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 12)	52 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 14)	53 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 22)	58 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 30, pre-dose)	62 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 12)	44 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 2)	3 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 2)	17 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 4)	11 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 22)	50 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 6)	10 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 4)	32 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 12)	17 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 14)	43 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 14)	22 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 6)	35 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 22)	20 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	DAS remission (Week 30, pre-dose)	54 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 1	ACR/EULAR remission (Week 30, pre-dose)	23 participants

Secondary

Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2

ACR/EULAR remission was considered if the scores on tender joint count, swollen joint count, hs-CRP (mg/dL), and PGA all were =\<1 or the score on the SDAI was =\<3.3. SDAI was calculated as the sum of number of tender and swollen joint count (using 28 joints), PGA, physician global assessment, and CRP (mg/dL). PGA was assessed on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. Physician global assessment was recorded on a 10 mm VAS ranging from 0 (very well) to 10 (very poor), where higher scores indicated more disease activity. DAS28 calculated from number of swollen joints and painful joints using the 28 joints count, CRP (mg/dL) and PGA using a 10 mm-VAS from 0 (very well) to 10 (very poor), where higher scores indicate worse health condition. DAS28 \<3.2: low disease activity, DAS28 \<2.6: remission.

Time frame: Week 38, 46 and 54 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 38)	29 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 46)	39 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 54, pre-dose)	42 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 38)	74 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 46)	76 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 54, pre-dose)	79 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 54, pre-dose)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 38)	15 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 38)	26 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 46)	30 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 46)	15 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 54, pre-dose)	18 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 46)	7 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 54, pre-dose)	13 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 54, pre-dose)	29 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 38)	25 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	ACR/EULAR remission (Week 38)	8 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 2	DAS remission (Week 46)	21 participants

Secondary

Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3

Time frame: Week 62, 70 and 78

Population: The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 62)	46 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 70)	50 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 78)	57 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 62)	85 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 70)	82 participants
Period 1: PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 78)	94 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 78)	39 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 62)	19 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 62)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 70)	40 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 70)	18 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 78)	19 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 70)	19 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 78)	18 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 78)	41 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 62)	34 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	ACR/EULAR remission (Week 62)	20 participants
Period 2: INX/PF-06438179	Number of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) and Disease Activity Score (DAS <2.6) Remission: Period 3	DAS remission (Week 70)	34 participants

Secondary

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1

ACR20 response: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; HAQ-DI and CRP.

Time frame: Week 2, 4, 6, 12, 22 and 30 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 2	105 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 4	170 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 6	187 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 12	210 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	week 22	205 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 30 (pre-dose)	197 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	week 22	213 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 2	121 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 12	214 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 4	190 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 30 (pre-dose)	209 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2, 4, 6, 12, 22 and 30 (Pre-dose): Period 1	Week 6	201 participants

Secondary

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2

Time frame: Week 38, 46 and 54 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 46	199 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 38	206 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 54 (pre-dose)	199 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 46	98 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 38	101 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 54 (pre-dose)	92 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 38	110 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 54 (pre-dose)	101 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 38, 46 and 54 (Pre-dose): Period 2	Week 46	99 participants

Secondary

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3

Time frame: Week 62, 70 and 78

Population: The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 70	199 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 62	199 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 78	192 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 70	87 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 62	89 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 78	86 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 62	103 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 78	98 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 62, 70 and 78: Period 3	Week 70	98 participants

Secondary

Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1

ACR50 response: \>=50% improvement in tender joint count, \>=50% improvement in swollen joint count improvement and \>=50% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP. ACR70 response: \>=70% improvement in tender joint count, \>=70% improvement in swollen joint count improvement and \>=70% in at least 3 of 5 remaining ACR core measures: participant assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, HAQ-DI and CRP.

Time frame: Week 2, 4, 6, 12, 14, 22 and 30 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 2)	24 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 4)	72 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 6)	88 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 12)	95 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 14)	116 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 22)	126 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 30, pre-dose)	125 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 2)	6 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 4)	22 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 6)	33 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 12)	46 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 14)	56 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 22)	56 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 30, pre-dose)	67 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 12)	40 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 2)	24 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 2)	6 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 4)	59 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 22)	45 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 6)	80 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 4)	13 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 12)	101 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 14)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 14)	108 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 6)	16 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 22)	116 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR70 (Week 30, pre-dose)	58 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 2, 4, 6, 12, 14, 22 and 30 (Pre-dose): Period 1	ACR50 (Week 30, pre-dose)	132 participants

Secondary

Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2

Time frame: Week 38, 46 and 54 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 38)	132 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 46)	135 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 54, pre-dose)	135 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 38)	77 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 46)	75 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 54, pre-dose)	82 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 54, pre-dose)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 38)	58 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 38)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 46)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 46)	55 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 54, pre-dose)	61 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 46)	63 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 54, pre-dose)	65 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 54, pre-dose)	35 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 38)	38 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR50 (Week 38)	75 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 38, 46 and 54 (Pre-dose): Period 2	ACR70 (Week 46)	33 participants

Secondary

Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3

Time frame: Week 62, 70 and 78

Population: The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 62)	132 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 70)	142 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 78)	150 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 62)	88 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 70)	92 participants
Period 1: PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 78)	98 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 78)	33 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 62)	59 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 62)	31 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 70)	35 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 70)	61 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 78)	57 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 70)	67 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 78)	73 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 78)	44 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 62)	41 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR50 (Week 62)	71 participants
Period 2: INX/PF-06438179	Number of Participants With an American College of Rheumatology 50% (ACR50) and ACR 70% Response at Week 62, 70 and 78: Period 3	ACR70 (Week 70)	44 participants

Secondary

Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1

EULAR response was based on DAS28 EULAR response criteria which was defined as good response = DAS28 change of \>1.2 with DAS28 =\<3.2; moderate response = DAS28 change of \>0.6 to =\<1.2 with DAS28 \>3.2-5.1 and no-response = DAS28 change of =\<0.6 with DAS28 \>5.1.

Time frame: Week 2, 4, 6, 12, 14, 22 and Week 30 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (good response)	24 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (moderate response)	172 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (no response)	121 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (good response)	61 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (moderate response)	162 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (no response)	89 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (good response)	65 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (moderate response)	168 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (no response)	79 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (good response)	90 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (moderate response)	149 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (no response)	71 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (good response)	97 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (moderate response)	137 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (no response)	76 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (good response)	103 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (moderate response)	125 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (no response)	73 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (good response)	101 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (moderate response)	133 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (no response)	58 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (moderate response)	162 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (good response)	34 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (good response)	94 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (moderate response)	161 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (no response)	66 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 2 (no response)	129 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (moderate response)	156 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (good response)	56 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (good response)	82 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (moderate response)	172 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (no response)	48 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 4 (no response)	87 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (moderate response)	155 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (good response)	64 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (no response)	55 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (moderate response)	181 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 14 (no response)	77 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 6 (no response)	74 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 30 (moderate response)	155 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 12 (good response)	88 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 1	Week 22 (good response)	96 participants

Secondary

Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2

Time frame: Week 38, 46 and Week 54 (pre-dose)

Population: The ITT Population was defined as all participants who were randomized to study treatment.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (good response)	107 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (no response)	29 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (no response)	33 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (moderate response)	126 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (good response)	110 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (moderate response)	109 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (no response)	34 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (moderate response)	132 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (good response)	118 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (moderate response)	64 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (good response)	51 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (moderate response)	62 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (no response)	28 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (good response)	46 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (no response)	28 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (good response)	53 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (moderate response)	56 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (no response)	20 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (no response)	25 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (good response)	49 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (good response)	50 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 38 (moderate response)	66 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (no response)	16 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (moderate response)	67 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (good response)	49 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 54 (moderate response)	62 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 2	Week 46 (no response)	17 participants

Secondary

Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3

Time frame: Week 62, 70 and Week 78

Population: The ITT population included all participants enrolled and treated with at least 1 dose of study treatment in Period 3.

Arm	Measure	Group	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (good response)	133 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (good response)	122 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (moderate response)	102 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (no response)	25 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (good response)	127 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (moderate response)	92 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (no response)	25 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (moderate response)	84 participants
Period 1: PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (no response)	22 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (moderate response)	48 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (good response)	58 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (good response)	50 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (moderate response)	45 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (good response)	56 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (moderate response)	56 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (no response)	15 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (no response)	11 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (no response)	17 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (no response)	15 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (good response)	52 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (moderate response)	53 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 70 (moderate response)	54 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (no response)	8 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (no response)	13 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (good response)	57 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 78 (good response)	57 participants
Period 2: INX/PF-06438179	Number of Participants With European League Against Rheumatism (EULAR) Response: Period 3	Week 62 (moderate response)	54 participants

Secondary

Number of Participants With Laboratory Abnormalities: Period 1

Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count, lymphocytes, neutrophils: \<0.8\*lower limit of normal (LLN); platelets: \>1.75\*upper limit of normal (ULN); white blood cell count: \<0.6\*LLN; basophils, eosinophils, monocytes: \>1.2\*ULN. liver function: bilirubin: \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\*ULN; protein, albumin: \<0.8\*LLN\>\</0\>1.2\*ULN; renal function:blood urea nitrogen,creatinine: \>1.3\*ULN; uric acid: \>1.2\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN,\>1.1\*ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\*LLN,\>1.5\*ULN). Participants with any laboratory abnormality in Period 1 were reported in this outcome measure.

Time frame: Baseline (Day 1) up to Week 30

Population: Safety population was defined as all participants who are randomized and receive at least 1 dose of study treatment, analyzed by actual treatment received. Here, Number of Participants Analyzed signifies participants who were evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With Laboratory Abnormalities: Period 1	245 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With Laboratory Abnormalities: Period 1	237 participants

Secondary

Number of Participants With Laboratory Abnormalities: Period 2

Time frame: Baseline (Week 30 pre-dose) up to Week 54

Arm	Measure	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With Laboratory Abnormalities: Period 2	154 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With Laboratory Abnormalities: Period 2	83 participants
Period 2: INX/PF-06438179	Number of Participants With Laboratory Abnormalities: Period 2	63 participants

Secondary

Number of Participants With Laboratory Abnormalities: Period 3

Time frame: Baseline (Week 54 pre-dose) up to Week 78

Arm	Measure	Value (NUMBER)
Period 1: PF-06438179	Number of Participants With Laboratory Abnormalities: Period 3	127 participants
Period 1: Infliximab-EU Remicade (INX)	Number of Participants With Laboratory Abnormalities: Period 3	72 participants
Period 2: INX/PF-06438179	Number of Participants With Laboratory Abnormalities: Period 3	61 participants

Secondary

Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (Nab) Status: Period 1

ADA positive results was defined as ADA titer level \>=1.30 and NAb positive was defined as NAb titer level \>=0.70.

Time frame: Baseline (Day 1) up to Week 30